Neuroendocrine neoplasms (NETs) are rare tumors that are increasing in incidence. NETs are characterized by heterogeneous biological behaviour, clinical presentation and course. A sensitive and specific diagnostic and prognostic circulating biomarker useful for all sites, grading and staging of neuroendocrine tumors is still an unmet need. The aim of this article was to review current neuroendocrine and oncologic scientific society guidelines and position statements, and propose recommendations for the most frequent clinical practice queries on circulating neuroendocrine tumors biomarkers. The authors searched for NCCN, NANETS, ESMO, ENETS, UKINETS, AME management guidelines or position statements available from PubMed up to 7th January 2016. From these results we chose guidelines or position statements published by scientific societies or institutions in USA, Europe and Italy with recognized expertise in neuroendocrine tumor patient management. The authors present suggestions for clinical practice based on this analysis.
INTRODUCTION
Neuroendocrine tumors (NETs) are rare but have been increasing in incidence. [1] NETs are characterized by heterogeneous biological behavior, clinical presentation, and course. NETs arise from neuroendocrine cells aggregate in classical endocrine glands --like adrenal, pituitary and parathyroid --but also in the diffuse neuroendocrine system (DNES).
An early diagnosis is crucial since lower survival was demonstrated in patients with metastatic disease. [2] However an interval of many years is reported from earliest symptoms to diagnosis. Symptoms are often nonspecific and do not lend themselves to identifying the specific underlying tumor. In addition, clinical presentations are protean and mimic a variety of other non-neoplastic diseases. [3] Many specialists may be individually involved from earliest signs and symptoms but a multidisciplinary team may be the most successsful approach to reduce time latency from symptoms to diagnosis and improve overall survival. [4] In this context the choice of circulating neuroendocrine biomarkers and interpretation of these values needs to be carefully considered with respect to the clinical presentation and other putative diagnoses. [5, 6] Many different diagnostic and therapeutic approaches are reported in real life NET manage-ment according to different physician expertise, accessibility of medical care in different countries, and financial reimbursement. Translation of guidelines and consensus into clinical practice is often difficult because suggestions are not always universally applicable.
The aim of our paper was to review current neuroendocrine and oncologic scientific society guidelines and position statements and provide recommendations for the most frequent clinical practice queries on circulating neuroendocrine tumor biomarkers.
We searched the National Comprehensive Cancer Network (NCCN), North American Neuroendocrine Tumor (NANETS), European Society of Medical Oncology (ESMO), European Neuroendocrine Tumor Society (ENETS), UK and Ireland Neuroendocrine Tumour Society (UKINETS) and Associazione Medici Endocrinologi (AME) for neuroendocrine tumor management guidelines or position statements using PubMed source. We terminated our search including results on 7th January 2016. From the PubMed results, we chose guidelines or position statements published by scientific societies or institutions in USA, Europe and Italy with recognized exper-tise in neuroendocrine tumor patient management. We present suggestions for clinical practice based on this analysis.
WHY SHOULD CIRCULATING NEUROENDOCRINE BIOMARKERS BE USED?
The current view of DNES was descending from Feyrter's 1938 initial discovery of neurons and endocrine cells sharing a common phenotypic program. These cells were characterized by the expression of markers such as neuropeptides, chromogranins, neuropeptide processing enzymes subtilase-like pro-protein convertases (SPC2 and SPC3) or dense core secretory granules. [7] All of these cells can secrete products such as peptides and biogenic amines that are tumour specific and may serve as markers for the diagnosis and follow-up of treatment. [8] In a few cases, clinical presentation is related to a single hormonal secretion as in insulinoma and gastrinoma, carcinoid syndrome or pheochromocytoma but more frequently the diagnosis is incidental or as a result of tumor bulk. [9] Circulating tumor biomarkers are readily available and should be implemented in clinical practice to diagnose and monitor patients with NETs. In fact, seventeen different circulating biomarkers have been identified for gastroenteric neuroendocrine tumors and more than 30 gut peptide hormone genes are known, which express more than 100 bioactive peptides. [8] In 2010 the World Health Organization published the new neuroendocrine tumors classification [10] and now there is consensus on routinely chromogranin A (CgA) and synaptophysin immunohistochemical assessment for neuroendocrine diagnosis. [11] On the other hand, the use of a single monoanalytical circulating biomarker for neuroendocrine tumors management -although frequently recommended -is now controversial [12] but, so far, unavoidable in NET management while waiting for new promising circulating biomarkers to be validated in the future.
WHICH CIRCULATING BIOMARKERS HAVE A ROLE IN NEUROENDOCRINE TUMOR MANAGEMENT?
The cytoplasm of neuroendocrine cells is occupied by a large number of secretory granules of varying electron densities, size and shape, and is the storage site of secretory products [i.e. serotonin, 5-hydroxytryptamine (5-HT), tachykinins and gastrin]. Upon specific stimulation, granules are translocated to the cell membrane and their content released by exocytosis. Granins are found as major, or principal, components of the soluble core of densecore secretory granules in neuroendocrine cells and are secreted in a physiologically regulated manner. There are 8 members in granin family and CgA and chromogranin B (CgB) are the most clinically interesting. [8] However, the precise function of individual granins is dependent on the presence of other granins and hormones produced by a specific neuroendocrine cell, the presence of proteolytic processing enzyme and their inhibitors and activators, as well as the density and localization of calcium pumps and exchangers. [13] Tumors of neuroendocrine origin usually present with increased plasma levels of serum or plasma CgA [8] but the sensitivity of CgA measurements in patient with NETs is only about 60-90% with a specificity of less than 50% due to concomitant therapy with protonpump inhibitors (PPIs) or intercurring oncological or non-oncological diseases. [14, 15] However a recent metaanalysis demonstrated that abnormally high circulating CgA levels are a characteristic feature of patients with NETs and could serve as non-invasive diagnostic markers of NETs in clinical practice. [16] CgA is considered a pan-neuroendocrine marker and notably highest concentrations were found in midgut NETs especially with liver metastasis. [17] [18] [19] Pancreastin is a post-translational processing product of CgA and was proposed as useful diagnostic marker because more standardized assays and lower PPIs exposure interferences than CgA are reported. A predictive and prognostic value was also demonstrated because pre-and post-surgical levels might better reflect neuroendocrine disease burden and outcome. [20] Other monoanalyte general neuroendocrine biomarkers used in managing NETs such as CgB, the cytoplasmatic glycolytic enzyme named neuron-specific enolase (NSE), and pancreatic polypeptide (PP) have been used with highest levels in small-cell lung cancer, poorly differentiated tumors and non-functioning pancreatic tumors, respectively, with low diagnostic performance. Also for CgB and NSE, sensitivity and specificity performances were reported inadequate for diagnosis and prognostic universal use [12] according to the National Institutes of Health (NIH) biomarker classification system criteria. [21] Gastrin is a diagnostic marker for Zollinger Ellison syndrome characterized by recurrent peptic ulcers and secretory diarrhea. Gastrin levels higher than 10 fold upper limit of normal in the setting of high gastric acid output is suggestive of gastrinoma. Determination of gastrin levels after a secretin test increases sensitivity in case of borderline levels. [22] Insulin is a specific marker of insulinoma and biochemical diagnosis depends on inappropriate insulin levels during a fasting glucose tolerance test. [23] Neuroendocrine tumors may secrete urinary 5-hydroxyindoleacetic acid (u-5HIAA), a metabolite of 5-HT but also vasoactive intestinal peptide (VIP), glucagon and somatostatin with specific syndromes such as carcinoid syndrome, watery diarrhea, sweet syndrome or association of gallstones, diabetes and steatorrhea. Even more rarely, tumors can secrete corticotropn releasing factor (CRF) and/or adrenocorticotropic hormone (ACTH), growth hormone releasing hormone (GHRH), arginine vasopressine (AVP), parathyroid-hormone related peptide (PTH-rp) or calcitonin with paraneoplastic Cushing's disease, acromegaly, inappropriate antidiuretic hormone secretion syndrome (SIADH).
Calcitonin is a peptide hormone that is normally secreted by thyroid C cells, but may be rarely produced ectopically by neuroendocrine tumors especially pancreatic NETs usually in association with other ectopically produced peptides and frequently with AVP [24] along with typical clinical symptoms of diarrhea and electrolyte disturbance.
Secretion of luteinizing hormone releasing hormone (LHRH), erythropoietin, cholecystokinin (CCK), renin and glucagon-like peptide 1 (GLP-1) in NETs are presented in only a few case reports or miniseries papers. [25] Diagnosis of these tumor subtypes is sometimes very difficult and so a multidisciplinary neuroendocrine team trained to suspect the disease based on symptoms is very important for early diagnosis. [6] For those paraneoplastic syndromes, the circulating biomarkers are not the starting point but the conclusion of a very difficult pathway from subtle and misleading clinical manifestation and biochemical alteration to diagnosis. For example potassium levels and euvolemic hyponatremia are 'per se' markers of possible ectopic Cushing disease or SIAD when presenting in a particular clinical context. [26, 27] During the natural course of disease, additional peptides could be secreted or co-secreted [28] resulting in different overlapping clinical manifestations with potential impacts on morbidity and mortality. These possibilities further complicate the puzzle that is NET patient management.
ARE CIRCULATING BIOMARKERS USEFUL IN THE DIFFERENTIATION BETWEEN FUNCTIONAL AND NON-FUNCTIONAL TUMOURS?
The spectrum of clinical presentation of NETs is highly variable. Many are incidental findings, whereas other patients present with mass effects of the primary tumour or metastases (usually liver). Most NETs are nonfunctional or secrete peptides with low biological consequences. Approximately 10-20% of NETs are functional and present with an associated endocrine syndrome. They include tumors that secrete insulin (insulinoma) and gastrin (gastrinoma) but more rarely also vasointestinal peptide (VIPoma), glucagon (glucagonoma), somatostatin (somatostatinoma), antidiuretic hormone (tumor responsible of SIAD) adrenocorticotropic hormone (ectopic ACTHoma), growth-hormone releasing hormone (ectopic GHRHoma), calcitonin (medullary thyroid carcinoma), parathyroid hormone (ectopic secretion of PTH), vasoactive compounds, including biogenic amines (tumor responsible of carcinoid syndrome) and catecholamines (pheochromocytoma). In these cases, a range of specific peptide hormones may also be measured and are useful as diagnostic and prognostic biomarkers. Both functional and nonfunctional NETs produce CgA but this marker does not distinguish between functional and nonfunctional tumors. [2] WHEN SHOULD BIOMARKERS TESTING BE PERFORMED?
Nonspecific circulating NET biomarkers do not have a crucial role in NET diagnosis and are not recommended for population screening in the absence of strong clinical or radiological evidence of tumor presence. [5, 6] CgA is correlated with tumor load and levels tend to be highest in metastatic cancer, particularly in the liver. [17] Recently however a meta-analysis reported a sensibility and specificity of 73% and 95% respectively for CgA with higher diagnostic accuracy. [16] u-5HIAA is mandatory in patients with carcinoid syndrome but not as useful in patients with foregut (bronchial, gastric) or hindgut (rectal) NETs or in most patients with pancreatic NETS which do not secrete serotonin. [29] Its value is dependent on tumor load and only very highly levels (> 5,000 µg/L) have been demonstrated to have a prognostic role in metastatic disease. [19] [20] [21] [22] [23] [24] [25] [26] [27] [28] [29] [30] There is consensus about weak diagnostic role for CgA and u-5HIAA in early tumor detection for non-functioning tumors. [5, 29, [31] [32] [33] The significance of NSE is limited in guidelines to poorly differentiated tumors but recent reports pointed to a possible prognostic role for this marker on progressionfree survival, overall survival, as a marker of treatment outcome in well differentiated, advanced pancreatic neuroendocrine tumors (pNET) during everolimus treatment [34] and more recently as a prognostic marker in gastroenteroNETs. [35] For syndromic patients the biomarkers should be evaluated according to signs and symptoms from the first diagnostic step. [29] In 2011, the NET Task Force of the National Cancer Institute GI Steering Committee recommended the inclusion of serial plasma CgA measurements into all prospective trials for validation as a prognostic and potential biomarker predicting response. [32] All guidelines recommend CgA in all NETs at diagnosis and during follow up as well as u-5HIAA for carcinoid tumors and specific markers according to clinical syndrome in functioning tumors. [ Table 1 ]
DO CIRCULATING BIOMARKERS CORRELATE WITH TUMOR BURDEN?
Although there are no data showing an absolute relationship between biomarker level and the degree of disease burden, higher levels are frequent in patients with metastasis, particularly in the liver. In other words, circulating biomarkers may reflect the tumor burden. Circulating markers are useful for monitoring specific tumors by providing a surrogate endpoint: CgA for the majority of cases, pancreastatin for hepatic tumor load, and neurokinin A for serotonin-secreting tumors of the small bowel. [33] In particular, circulating CgA is higher in patients with large metastases compared with localized disease or even limited hepatic involvement (when assessed as < 25%, 25-50%, > 50%) and correlates with survival. In addition, CgA levels are reduced after hepatic resection or transplantation. In a retrospective study, a CgA decrease of 80% or more was predictive of complete symptom resolution and disease stabilization. By contrast, reduction of urinary 5-hydroxyindoleacetic acid concentrations of 80% or more (or normalization) was predictive of symptomatic relief but not of disease stabilization. [45] Despite the fact that gastrinomas show high circulating CgA values even in the absence of liver metastasis, gastrin levels are generally proportional to tumor burden and highest gastrin levels are present in patients with metastatic disease. In addition, gastrin seems higher in pancreatic compared to duodenal primary tumors, with no discernible difference between sporadic and multiple endocrine neoplasia (MEN1) or Zollinger Ellison syndrome patients. [46] On the contrary, authors of a recent consensus agreed that circulating biomarkers levels in patients with neuroendocrine tumors do not correlate with tumor grade and do not differentiate low-level malignancy from high-grade disease. [12] 
SHOULD CIRCULATING BIOMARKERS BE USED IN DISEASE FOLLOW UP?
When specific circulating biomarkers are elevated at the diagnosis in a patient there is indication to follow these over time. If new signs and symptoms emerge, it is necessary to test for new paraneoplastic syndromes according to clinical presentation. [6] All guidelines [ Table 1 ] recommend the use of CgA for follow up in all NETs even though there is an absence of prospective studies supporting its use. Give some written information how to collect 24 h urine and to conserve. If result is doubtful and crucial for diagnostic and therapeutic choose repeat
Perform two consecutive 24-h urine collections and take mean value of these two especially when collection required for diagnosis or when crucial for terapeutic choose
Recommend only certificated laboratories with high quality control certification
Keep in mind others pathological causes of elevated u-5HIAA as coeliac and Whipple's disease, intestinal stasis and cystic fibrosis
Exclude from the diet from 72 h preceding and during urine collection plums, pineapples, bananas, eggplants, tomatoes, avocados, walnuts, avocados, kiwi, pecans, coffee, tea, cocoa, chocolate, vanilla, sweets and cookies SSA is known to decrease u-5HIAA. Assays for diagnostic purposes should be made in patients not on somatostatin analogues therapy
In the follow up setting urinary samples need to be collected on stable or comparable SSA doses Report in patient medical record type of somatostatin analogue and frequency of administration and eventually subcutaneous octreotide performed in the last 24 h before determination NETs: neuroendocrine tumors; PPIs: proton pump inhibitors; SSA: somatostatin analogues; u-5HIAA: urinary 5-Hydroxy-indolacetic acid
SHOULD BIOMARKERS REFLECT INTERVENTION?
CgA has been used in gastroenteric NETs as a predictive biomarker to identify patients most likely to have durable responses to long acting somatostatin analogue therapy. [47] Further, early decreases in CgA after somatostatin analogues plus everolimus was predictive of early response in pNET patients. [34] Increases in CgA levels after radical surgery in a large Italian observational study was reported to be predictive of tumor relapse 9-12 months before the clinical and radiological evidence of disease recurrence. [48] In a recent paper, CgA was an early predictor of recurrence 6 months before radiological progression in metastatic NETs. [49] A reduction of > 80% in CgA after cytoreductive surgery was shown to predict disease control [50] and reduction of CgA was observed after successful peptide receptor radionuclide therapy [51] and liver transplantation. [52] 
HOW TO AVOID MISINTERPRETATION OF CGA, GASTRIN AND U-5HIAA IN CLINICAL PRACTICE?
There are many conditions that interfere with CgA and u-5HIAA measurements. For CgA there is no universally accepted CgA assay and the different methodologies can lead to confusing results. Many physiological conditions as stress, pregnancy or exercise can increase circulating CgA levels and the same is true for many drugs and nonneuroendocrine diseases. U-5HIAA measurements also have inherent pitfalls since they require a 24 h urine collection and are subject to interference by dietary habits. [2, 5, 8, 9, [13] [14] [15] 29, 31, 33] Tables 2 and 3 show the most important pitfalls and bottlenecks and possible remedies in CgA, gastrin and u-5HIAA interpretation and provide suggestions to reduce interference in circulating biomarker measurements for more accurate tumor management.
MONOANALYTE OR MULTIANALYTES?
The identification of effective biomarkers in patients with NETs is a high priority. In a recent Delphi consensus, the panel of neuroendocrine experts agreed that an acceptable standard for a diagnostic biomarker should have a sensitivity of at least 80%, specificity of at least 90%, and positive and negative predictive values of each at 80% or more. [12] In addition, the biomarker should be able to provide information regarding the proliferative and metastatic capacity of a tumor, the identification of surgical and medical treatment effectiveness and correlate with patient survival. Unfortunately current universal circulating biomarkers are not able to provide this standard and, in particular, the role of CgA in the diagnosis of neuroendocrine tumors is decreasing.
The principal limitation in the measurement of circulating CgA is the absence of a gold standard assay and wide variability of results from different kits and laboratories. In addition, false positive results are reported as a result of other neoplasia (prostate and breast cancer and hepatocellular carcinoma) and common conditions (kidney, liver or heart failure, chronic gastritis, inflammatory bowel disease, PPI use, essential hypertension and physical stress). In addition, the current biomarkers used for gastroenteropancreatic NETs are inadequate for bronchopulmonary NETs and vice versa. For these reasons, a multianalyte approach would likely be more effective compared to a monoanalyte circulating biomarker. To this end, a specific multianalyte assay with algorithmic analyses (MAAA) named NETest has recently been developed. NETest is a PCR-based, 51-transcript signature that is based on correlating and normalizing multiple sets of variables that represent gene clusters specific to NETs and their biological behavior. The use of this blood-based test is proposed to facilitate early detection of disease recurrence and to predict therapeutic efficacy. The diagnostic performance of MAAAs was better when compared to CgA (93-98% vs. 50-80%) [53, 54] exceeding the performance criteria proposed by an expert panel convened to evaluate NET biomarkers. MAAAs and NETest in particular may improve diagnostic accuracy and offer better interdisciplinary perspective than single analyte testing.
IS THERE A CLINICAL ROLE FOR NOVEL BIOMARKERS?
Recently, several novel biomarkers for NETs have been developed using an integration of genomics and technology platforms. In addition to gene transcript by MAAAs, circulating tumor cell (CTC) and microRNA (miRNA) analyses have been proposed. [12] Khan et al. [55] showed that the number of CTC detected in patients with neuroendocrine tumors was comparable to other tumors in which CTC have been shown to have prognostic relevance. In this study, 47% of patients with midgut (n = 101) and 24% of patients with pancreatic (n = 42) tumors had ≥ two CTC detected. Presence of CTC was clearly associated with increasing tumor burden and weakly with tumor grade. In a more recent, large prospective study, the same group demonstrated that changes in CTC were associated with response to treatment and overall survival in metastatic neuroendocrine tumors, suggesting CTC may be useful as a surrogate marker to direct clinical decision making. [56] Although there is an increasing interest in CTC as a biomarker, recent consensus concluded that CTC analyses have several technical limitations and need further validation before being adopted into routine clinical practice. [12] There is also increasing interest in miRNAs as clinical biomarkers of tumorigenesis, treatment response and outcomes, but to date clinical data are scarce and clinical application challenging. Similarly, there are several novel monoanalyte assays (i.e. connective tissue growth factor for carcinoid heart disease (CCN2) or paraneoplastic Ma antigen 2 (PNMA2) for small intestinal neuroendocrine tumors, but these analyses are not available in clinical practice. [12] Further, panelists of the recent Delphi consensus gave the strongest support to the use of emerging biomarkers in multianalyte technology based on genomics. [12] 
CONCLUSION
To date, the identification of sensitive, specific and reproducible NET circulating biomarkers for the prediction, diagnosis, prognosis and classification of NETs and to evaluate changes during therapy has been limited [12] and remains an unfulfilled unmet medical need as defined by the 2007 National Cancer Institute NET meeting. [57] There are no specific circulating monoanalyte biomarkers for neuroendocrine tumors that fulfill the NIH recommended criteria and the search continues for markers with diagnostic and prognostic capabilities. Since Feyrter have discovered the neuroendocrine equivalent of Pandora's Box, a unique relationship between these various neuroendocrine peptides and different tumors has not been found yet. [7] We are hopeful that in the era of Precision Medicine, specific circulating markers or a multianalyte panel for specific tumor types can be developed for NETs giving more reliable diagnostic and prognostic information. The road is long and new, robust prospective studies in different neuroendocrine tumors settings are required before new accurate biomarkers are validated and implemented into routine clinical practice.
Financial support and sponsorship
Nil.
Conflicts of interest
There are no conflicts of interest.
Patient consent
No patient involved.
Ethics approval
This article does not contain any studies with human participants or animals.
